Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Quinazoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.77 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinazoline SCHEMBL16444698 | 1.00 | EGFR (0.77) | EGFRPIK3CDPIK3CACHRNB2CHRNA4 | |
| Quinazoline SCHEMBL29144630 | 0.93 | EGFR (0.71) | EGFRPIK3CDPIK3CACHRNB2CHRNA4 | |
| Quinazoline SCHEMBL27875528 | 0.92 | EGFR (0.77) | EGFRPIK3CDPIK3CACHRNB2CHRNA4 | |
| Quinazoline SCHEMBL6569237 | 0.91 | EGFR (0.69) | EGFRPIK3CDPIK3CACHRNB2CHRNA4 | |
| Quinazoline SCHEMBL3718090 | 0.88 | EGFR (0.65) | EGFRPIK3CDPIK3CACHRNB2CHRNA4 | |
| Quinazoline SCHEMBL29356169 | 0.88 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2ALDH1A1 | |
| Quinazoline SCHEMBL29490398 | 0.88 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2ALDH1A1 | |
| Quinazoline SCHEMBL22833783 | 0.88 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2ALDH1A1 | |
| Quinazoline SCHEMBL5920 | 0.88 | EGFR (1.00) | EGFRPIK3CDPIK3CATDO2ALDH1A1 | |
| Quinazoline SCHEMBL5579413 | 0.86 | EGFR (0.95) | EGFRPIK3CDPIK3CATDO2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102942529-B | 4-(4-substituted piperazine)-5,6,7-trialkoxy quinazoline type compound as well as preparation method and application of 4-(4-substituted piperazine)-5,6,7-trialkoxy quinazoline type compound | UNIV GUIZHOU | 2015-06-24 | — | — | CN | claimed |
| CN-102942529-A | 4-(4-substituted piperazine)-5,6,7-trialkoxy quinazoline type compound as well as preparation method and application of 4-(4-substituted piperazine)-5,6,7-trialkoxy quinazoline type compound | UNIV GUIZHOU | 2013-02-27 | — | — | CN | claimed |
| US-20080318963-A1 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives | REXAHN PHARMACEUTICALS, INC. (US) | 2008-12-25 | — | — | US | claimed |
| EP-1819698-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | Rexahn Pharmaceuticals, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2006054830-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | REXAHN PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | claimed |
| US-RE49897-E1 | Salts of a dihydroquinazoline derivative | AIC246 AG & CO. KG (DE) | 2024-04-02 | — | — | US | disclosed |
| CN-116570598-A | Application of phenylpiperazine quinazoline compounds in preparation of P-gp inhibitor drugs | 暨南大学 | 2023-08-11 | — | — | CN | disclosed |
| CN-113754595-A | Preparation method and application of 6-fluoroquinazoline derivatives containing disulfide structures | 贵州大学 | 2021-12-07 | — | — | CN | disclosed |
| US-10968214-B2 | KRas G12C inhibitors | ELI LILLY AND COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2020081282-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20200115375-A1 | KRAS G12C INHIBITORS | ELI LILLY AND COMPANY | 2020-04-16 | — | — | US | disclosed |
| US-10287254-B2 | Salts of a dihydroquinazoline derivative | AICURIS GMBH & CO. KG (DE) | 2019-05-14 | — | — | US | disclosed |
| CN-1186322-C | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2005-01-26 | — | — | CN | disclosed |
| EP-0892790-B1 | NEW QUINAZOLINE-4-AMINO-2-(PIPERIDINE-1-YL-4-SUBSTITUTED) DERIVATIVES HAVING ANTI-HYPERTENSIVE ACTIVITY, A METHOD FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ROTTA RESEARCH LAB (IT) | 2004-04-14 | — | — | EP | disclosed |
| CN-1441779-A | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMACEUTICAL CO L (JP) | 2003-09-10 | — | — | CN | disclosed |
| US-5985885-A | USEFUL IN THE TREATMENT OF HYPERTENSION, CONGESTIVE HEART FAILURE, PROSTATE HYPERTROPHY, VARIOUS URINARY TRACT DISORDERS AND PATHOLOGICAL SYMPTOMS CAUSED BY HYPERACTIVITY OR DISFUNCTIONING OF THE NORADRENERGIC NEURAL SYSTEM | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1999-11-16 | — | — | US | disclosed |
| CN-1043141-C | Heterocyclic amines useful in the therapy of the asthma and of the inflammation of the respiratory tract | BOEHRINGER MANNHEIM ITALIA (IT) | 1999-04-28 | — | — | CN | disclosed |
| EP-0892790-A1 | NEW QUINAZOLINE-4-AMINO-2-(PIPERIDINE-1-YL-4-SUBSTITUTED) DERIVATIVES HAVING ANTI-HYPERTENSIVE ACTIVITY, A METHOD FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997037979-A1 | NEW QUINAZOLINE-4-AMINO-2-(PIPERIDINE-1-YL-4-SUBSTITUTED) DERIVATIVES HAVING ANTI-HYPERTENSIVE ACTIVITY, A METHOD FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ROTTA RESEARCH LABORATORIUM S.P.A. (IT) | 1997-10-16 | — | — | WO | disclosed |
| CN-1088580-A | The heterocyclic amine that is used for the treatment of respiratory tract asthma and inflammation | BOEHRINGER MANNHEIM ITALIA (IT) | 1994-06-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318963-A1 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives | HRAS, CDK4, KRAS | EGFR 1556/4885PIK3CD 812/4885PIK3CA 403/4885 |
| US-20200115375-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | EGFR 57/4885PIK3CD 379/4885PIK3CA 100/4885 |
| US-10968214-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | EGFR 57/4885PIK3CD 379/4885PIK3CA 100/4885 |
| US-10287254-B2 | Salts of a dihydroquinazoline derivative | BAD, IRF3, VHL | EGFR 4009/4885PIK3CD 3176/4885PIK3CA 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.